SPECT/CT-Guided Surgical Removal of a Positive External Iliac Sentinel Node in Primary Umbilical Melanoma: Report of a Case, and Up-to-Date Review of the Literature

Franco Picciotto1, Adriana Lesca2*, Luca Mastorino3, Elena Califaretti2, Luca Conti4, Pietro Quaglino3, Simone Ribero3, Virginia Caliendo1 and Désirée Deandreis2

1 Dermatologic Surgery Section, Department of Surgery, Azienda Ospedaliera Universitaria (AOU) Città della Salute e della Scienza, Turin, Italy, 2 Division of Nuclear Medicine, Medical Sciences Department, University of Turin, Azienda Ospedaliera Universitaria (AOU) Città della Salute e della Scienza, Turin, Italy, 3 Dermatology Clinic, Medical Sciences Department, University of Turin, Turin, Italy, 4 Surgical Pathology Section, Oncology Department, University of Turin, Azienda Ospedaliera Universitaria (AOU) Città della Salute e della Scienza, Turin, Italy

Primary umbilical melanoma is rare tumor, representing about 5% of all umbilical malignancies. The lymphatic drainage from the tumor is challenging and can be to inguinal, axillary and retroperitoneal nodes. Dynamic and static lymphoscintigraphy with single-photon emission tomography/computed tomography (SPECT/CT) and sentinel lymph node biopsy (SLNB) is a widely validated technique in patients with clinically localized melanoma to search for and quantify nodal spread of cutaneous melanoma. Moreover, it offers the surgeon the preoperative information about the number and location of the sentinel lymph nodes (SLNs), which makes SLNB easier and quicker. This is the first report of an ulcerated thick melanoma of the umbilicus metastasizing only to an external iliac lymph-node without involvement of superficial inguinal SLNs. The preoperative high-resolution ultrasound (HR-US) examination of the regional lymph node field had been normal. This case-report shows how addition of SPECT/CT to planar imaging in a patient with clinically localized umbilical melanoma can help avoid incomplete SLNB when a deep SLN is not removed. A literature review of umbilical melanoma is also provided.

Keywords: umbilical melanoma, navel melanoma, sentinel node, lymphoscintigraphy, sentinel node biopsy, SPECT/CT, thick melanoma
INTRODUCTION

The umbilicus is a unique anatomical site with complex vascular embryonic remnants. It is a depressed scar surrounded by a natural skinfold that measures 1.5-2 cm in diameter and lies anatomically in the middle of the abdomen (1). The umbilicus is a weak point in the abdominal wall and is vulnerable to hernia formation (2).

Neoplasms are rare in the umbilicus and can be either (Sister Mary Joseph nodule) or benign. Primary umbilical melanoma is rare, representing about 5% of all umbilical malignances (3). Excision of the entire umbilicus, including its attachment to the peritoneum, is recommended. In some cases, reconstruction of the navel region can be performed. Sentinel lymph node biopsy (SLNB) is performed for staging and to improve survival in node positive patients with intermediate thickness lesions but also for prognostic evaluation in patients with thick melanoma (i.e. \( \geq 4 \) mm) (4–6). A negative SLNB is associated with prolonged recurrence-free survival, disease-specific survival, and overall survival compared to patients with a positive SLNB (4). We herein report a case of thick primary umbilical melanoma.

The aim of this paper is to emphasize the key role of single-photon emission computed tomography with computed tomography (SPECT-CT) in identifying all sentinel lymph nodes, enabling proper staging in the age of effective adjuvant systemic therapy. The literature about this rare location of melanoma is reviewed.

CASE REPORT

A 45-year-old man presented to our hospital with an umbilical skin tumor (Figure 1A) that had been present for about seven years and that increased in size with occasional bleeding in the last 12 months. The patient signed an informed consent for the procedures performed as well as for the use of clinical data for research. Due to the Sars-Cov2 pandemic, the patient had delayed the dermatology consultation despite an event of traumatic bleeding. No lymph node swelling was palpable on either side the inguinal regions and in the axillae. The patient underwent an excisional biopsy revealing the tumor to be melanoma. The Breslow depth was 11 mm, Clark IV with a mitotic rate of 9 per mm². Ulceration and microscopic satellites were present. Immunostaining to S-100 protein, HMB-45, and Melan-A were all positive. The AJCC classification was pT4bN1c Total body computed tomography (CT) and 18F-FDG positron emission tomography with computed tomography (PET/CT) showed no metastases and no pathological regional lymph nodes were found by means of preoperative high resolution ultrasound (HR-US). The patient underwent wide local re-excision of the primary tumor site and SLNB. Lymphoscintigraphic mapping was performed the day before the surgery, using a double head gamma camera equipped with a CT (Discovery NM/CT 670, GE Company Milwaukee, Wisconsin, USA). A dose of 25.9 MBq of \( ^{99m}\text{Tc} \) labeled Nanocolloid (Nanotop – Rotop Pharmaka GmbH, Germany) equally subdivided in four syringes, in a volume of 0.10 ml, was intradermally administered around the excisional biopsy site. Dynamic imaging (1 minute per frame in a matrix of 128x128 for 30 minutes) was started, showing bilateral lymphatic drainage to the inguinal region. Five-minute static acquisition was performed following the dynamic phase and delayed static images were then acquired in a matrix of 256x256. Subsequently, planar imaging of the thorax was carried out and SPECT/CT of the sub-umbilical region. Five-minute early static acquisition was performed with 256x256 matrix over inguinal and thorax regions, showing no axillary lymphatic drainage. Delayed static images after two hours were acquired with 256x256 matrix for five minutes over the pelvic region. The study was completed by SPECT/CT of the sub-umbilical region (step-and-shoot mode, 25 s/3°, in a 128x128 matrix size).

![FIGURE 1](image-url)
Summed dynamic phase images (Figure 1B) showed an intense focus in the left inguinal area that was considered a SLN; however, another focus with its direct lymphatic pathway gradually appeared medially to this one. Because of its direct and separate drainage from the injection site, it was deemed another SLN (Figure 1C). In the right inguinal area, another hot focus was quickly visualized, and classified as a contralateral right SLN. Furthermore, a faint focus appeared medially to the previous one, connected with it by a lymphatic collector, and it was deemed as a second-echelon node. SPECT-CT confirmed the presence of three SLNs in the inguinal area, one on the right side and two on the left. However, the second SLN in the left groin was found to be in the iliac area, adjacent to the inguinal canal, retropubic, near the anteromedial margin of the acetabulum. It had a normal appearance on CT images (Figures 1D, E). Also, the second-echelon node, detected medially on the right side, was found to be an external iliac node. No SLNs were seen on planar imaging of the thorax. The SLNs were marked on the skin in orthogonal projections.

Using general anesthesia, all three SLNs were identified after intradermal injection of vital blue dye and with intra-operative use of a hand-held gamma ray detection probe. All three sentinel nodes were stained blue and were removed.

The primary tumor was excised including the umbilicus, with >2-cm lateral margins, and down to the underlying peritoneum (Figure 2). At histopathological analysis, the two superficial bilateral inguinal SLNs were negative. The deep one taken from the left iliac site was positive for metastasis, with a size of 1.6 x 1.2 x 0.6 cm and a tumor burden of 1.5 mm as maximum diameter of largest deposit. This allowed a more precise pathological staging as pT4bN2C and an adequate stratification of risk, based on the coexistence of ulceration along with high sentinel nodal tumor burden (i.e. >1.0 mm) (7).

Inguino/iliac/obturator lymph node dissection was not performed, since active surveillance has been demonstrated to have equivalent survival outcomes to completion lymphadenectomy (8). Given positive result for BRAF V600E mutation, the patient was started on adjuvant combination therapy with BRAF and MEK inhibitors along with focused HR-US surveillance of nodal basins. At follow-up, 4 months after surgery, HR-US of nodal basins (axillary and inguinal), brain MRI with contrast and Whole Body 18F-FDG PET/CT were all normal.

**DISCUSSION**

Primary cutaneous malignant melanoma involving the umbilicus is a rare entity and, to our knowledge, only 32 cases have been described in the literature since 1975 (9–24). Given the anatomical site of the umbilicus, lymphatic drainage and thus dissemination, may occur to the inguinal area and to the axilla (25), but also to parailiac lymph nodes, even without involvement of the superficial inguinal nodes.

Although the data were incomplete in most publications, the literature review showed some specific features of navel melanoma. First, there was a marked female prevalence (24 females and 8 males) (Table 1). It has been suggested that the presence of terminal body hairs in male patients could represent a natural UV-protective barrier (9). The median age of diagnosis was 58 years, with a great range of 28-84 years. The majority of melanomas were of the nodular type with a vertical growth phase. There were three cases of in situ melanoma. The median Breslow thickness was 2.5 mm with a range of 0.42-11, reflecting that navel melanoma is often detected at a fairly advanced stage, suggesting that melanoma arising in this body site is more aggressive than elsewhere.

Supporting this hypothesis is the finding that six of the seventeen patients for whom disease follow-up data were available have developed a disease relapse and died of...
**TABLE 1 | Summary of literature findings on umbilical melanoma.**

| Author            | Sex/Age | Type                      | Breslow (mm) | Clark | Time from occurrence | Pre-existing nevus | SLNB | Therapy                              | Relapse | Survival | BRAF   |
|-------------------|---------|---------------------------|--------------|-------|----------------------|-------------------|------|--------------------------------------|---------|----------|--------|
| Ki Wei Tan (9)    | F/59    | SSM                       | 6.4          | IV    | 2 weeks              | Yes               | Yes  | Adjuvant Nivolumab                   | Nodal Lung - Bone | NA       | Wild-type |
| Kovitwanichkanont | F/74    | Nodular amelanotic ulcerated | 21           | IV    | Long standing        | Yes               | Yes  | Adjuvant Nivolumab                   | 4 months loco-regional | Alive    | Wild-type |
| (11) 2020         |         |                           |              |       |                      |                   |      |                                      |                     |          |         |
| Charles (10)      |         |                           | 2.2          | IV    | Several years        | NA                | No   | Therapy                              | 3 years, alive     |          |         |
| (7 cases)         |         |                           | 6.41         | (0.65-15.6) | 5 (4 at histology)   |                   |      |                                      |                     |          |         |
| Costa-Silva (12)  | F/81    | Ulcerated                 | 5.6          |       |                      |                   |      |                                      |                     |          |         |
| Suzuki (13) 2016  | F/83    | Ulcerated                 | 11           | IV    | 2 weeks              | No                | Yes  | No Anti-MEK/anti-BRAF/Iplimumab      | 15 months, alive   | 18 months, died | Mutant |
| Di Monta (14) 2015 | F/33   | Nodular Melanoma ulcerated | 4.0          | IV    | 2 weeks              | Yes               | Yes  | Anti-MEK/anti-BRAF/Iplimumab        | 6 months - Local then diffuse | 21 months, alive |         |
| Song (15) 2013    | M/62    | SSM ulcerated             | 3            | IV    | 1 month              | Reported nevus 4 years before | Yes |                                      | 36 months, alive   |          |         |
| Navysany (16) 2013 | F/NA   | In situ                   | 4.1          |       |                      | Present at histology | Yes |                                      | 3 months, alive    |          |         |
| Dessy (17) 2013   | F/36    | In situ                   | Present at histology |       |                      |                   |      |                                      |                     |          |         |
| Papalas (3) 2011  | M/41    | Nodular Melanoma          | 1.75         | I     |                      |                   | Yes  |                                      |                     |          |         |
| Papalas (3) 2011  | F/28    | In situ                   | 1.87         | IV    |                      |                   | Yes  |                                      |                     |          |         |
| Papalas (3) 2011  | F/84    | SSM ulcerated             | 4.16         | IV    |                      |                   | Yes  |                                      |                     |          |         |
| Papalas (3) 2011  | M/35    | In situ                   | 0.42         | II    |                      |                   | Yes  |                                      |                     |          |         |
| Zaccagna (18) 2011 | F/60   | VGP                       | 2.8          | IV    |                      |                   | Yes  |                                      |                     |          |         |
| Cecchi (19) 2009  | F/77    | Ulcerated, achromic       | 2.3          | IV    | 4 years              | Yes               | Yes  |                                      |                     |          |         |
| Mangas (20) 2008  | M/63    |                           | 0.8          | III   | Unknown              | Present at histology | Yes |                                      |                     |          |         |
| Campos-Munoz (21) | F/34    | SSM                       | 1.06         | III   | 1 month              | Present at histology | Yes |                                      |                     |          |         |
| Meine (22) 2003   | F/69    | SSM - VGP                 | 1.88         | IV    | 2 months             | Reported nevus   | Yes  | Dacarbazine                          | Local relapse 3 year, visceral | 10 months, died |         |
| Colonna (23) 1999 | F/58    | NM plus satellites         | 0.88         | V     | 2 months             | Reported nevus   | Yes  | Dacarbazine                          | 9 months, visceral  |          |         |
| Colonna (23) 1999 | M/30    | V GP                      | 1.3          | V     | 18 months            | Reported nevus   | Yes  | Dacarbazine                          | 30 days, died      |          |         |
| Hashiro (24) 1998 | M/58    | SSM-VGP                   | 2.3          | IV    | 4 years              | Yes               | Yes  |                                      |                     |          |         |

SLN, Sentinel Node Biopsy; NM, Nodular Melanoma; SSM, Superficial Spreading Melanoma; VGP, Vertical-Growth-Phase; NA, Not Available.
melanoma after a time interval of 30 days to 28 months from the initial operation. SLNB is a crucial element in the management of melanoma patients (26, 27). It provides prognostic and staging information, improves regional disease control in cases where complete lymphadenectomy is performed, improves survival of node-positive patients in cases of an intermediate Breslow thickness melanoma and helps selecting patients who may benefit from adjuvant systemic treatment (27). Only eight of the articles in our review reported performance of SLNB in a total of fourteen patients with primary umbilical melanoma, with nodal positivity in only four patients.

The main site of metastasis was the inguinal node field in all four patients, with a total of five positive lymph nodes. One of these patients also had a positive SLN in the left axilla (Table 2).

It is essential to use the correct definition of a SLN and to select an accurate technique for its retrieval. Most experts define a sentinel node as any lymph node on a direct lymphatic drainage pathway and most also use planar lymphoscintigraphy starting with dynamic imaging to delineate the lymph vessels. This is followed by delayed static imaging and SPECT/CT. SPECT/CT superimposes the anatomical information of CT onto the functional images of lymphoscintigraphy to reveal the precise 3D anatomical location of SLN(s) (28, 29).

The images are displayed as tomographic sections in the transaxial, coronal, sagittal planes and can also be displayed as 3D volume rendering images. It can provide additional information, especially when the tumor is located in the head, neck, or torso (28) and helps to localize pelvic SLNs (29). Moreover, the use of SPECT/CT is associated with a higher SLN excision rate and lower local relapse rate (30).

In brief, SPECT/CT defines with greater accuracy the anatomical position of SLN(s), clarifies unusual drainage pathways, and identifies pathologically enlarged lymph nodes (31). At our institution, SPECT/CT is performed routinely in addition to planar imaging. In the subject of this case report the role of the SPECT/CT was decisive, allowing the surgeon to be guided toward an external iliac positive sentinel lymph node, located below the fascia of the external oblique muscle.

In the present case, removal of the only iliac metastatic node led to a more precise classification (pT4bN2C), without changing the stage (III C).

This is furthermore the first reported case of a lymph node metastasis spread only in an external iliac node, without involvement of the superficial inguinal sentinel nodes. Now that adjuvant systemic therapy is becoming common in patients with even minimal nodal involvement, SLNB is becoming even more important.

**CONCLUSION**

In the new era of effective adjuvant therapy, accurate staging of patients with melanoma has become even more important than it was before. The current case report demonstrates how accurate staging can be accomplished in a patient with a melanoma in the umbilicus, a rare location at the crossroads of lymphatic drainage pathways. Dynamic lymphoscintigraphy indicated the SLNs and SPECT/CT showed the node that eventually proved to be the only metastatic one in its unusual anatomic habitat in the pelvis.

**DATA AVAILABILITY STATEMENT**

The original contributions presented in the study are included in the article-supplementary material. Further inquiries can be directed to the corresponding author.

**ETHICS STATEMENT**

Ethical approval was not provided for this study on human participants because this is a case report and a review of the literature. The patient signed an informed consent for the use of own data. The patients/participants provided their written informed consent to participate in this study. Written informed consent was obtained from the individual(s) for the publication of any potentially identifiable images or data included in this article.

**AUTHOR CONTRIBUTIONS**

DD, AL, and EC took care of scintigraphic investigation. FP and VC conducted the surgery. LC carried out the histopathological study. PQ, SR, and LM revised the literature. All authors contributed to the article and approved the submitted version.
REFERENCES

1. Mazzocchi M, Triginano E, Armenti AF, Figus A, Dessy LA. Long-Term Results of a Versatile Technique for Umbilicoplasty in Abdominoplasty. Aesthetic Plast Surg (2011) 35(4):456–62. doi: 10.1007/s00266-010-9627-2
2. Fathi AH, Soltanian H, Saher AA. Surgical Anatomy and Morphologic Variations of Umbilical Structures. Am Surg (2012) 78(5):540–4. doi: 10.1177/000318821207800534
3. Papalas JA, Selim MA. Metastatic vs Primary Malignant Neoplasms Affecting the Umbilicus: Clinicopathologic Features of 77 Tumors. Ann Diagn Pathol (2011) 15(4):237–42. doi: 10.1016/j.anndiagpath.2010.12.004
4. Yamamoto M, Fisher KJ, Wong YJ, Kosco JM, Konstantinovic MA, Koscso JM, et al. Risk Stratification of Sentinel Node–Positive Melanoma Patients Defines Surgical Management and Adjuvant Therapy Treatment Considerations. Eur J Cancer (2018) 96:25–33. doi: 10.1016/j.ejca.2018.02.022
5. Faries MB, Thompson JF, Cochran AJ, Andibacka RH, Mozillo N, Zager JS, et al. Completion Dissection or Observation for Sentinel-Node Metastasis in Melanoma. N Engl J Med (2018) 378(3):2211–22. doi: 10.1056/NEJMoa1613210
6. Gajdos G, Griffith KA, Wong SL, Johnson TM, Chang AE, Cimmino VM, et al. Is There a Benefit to Sentinel Lymph Node Biopsy in Patients With T4 Melanoma? Cancer (2009) 115:5752–60. doi: 10.1002/cncr.24660
7. Verder D, van Klaveren D, van Akkooi ACJ, Rutkowski P, Powell B, Robert C, et al. Risk Stratification of Sentinel Node–Positive Melanoma Patients Defines Surgical Management and Adjuvant Therapy Treatment Considerations. Eur J Cancer (2018) 96:25–33. doi: 10.1016/j.ejca.2018.02.022
8. Faries MB, Thompson JF, Cochran AJ, Andibacka RH, Mozillo N, Zager JS, et al. Completion Dissection or Observation for Sentinel-Node Metastasis in Melanoma. N Engl J Med (2018) 378(3):2211–22. doi: 10.1056/NEJMoa1613210
9. Tan KW, Chan JY. Primary Cutaneous Umbilical Melanoma. Ann Acad Med Singap (2021) 50(2):177–8. doi: 10.47102/annals-acadmedsg.2020371
10. Charles KB, Chan MP, Smith NR, Orsini AP, Noh IK, Kozlow JH, et al. Primary Cutaneous Umbilical Melanoma: The Michigan Experience. Dermatol Surg (2020) 46(3):312–8. doi: 10.1097/DSS.0000000000002024
11. Kovitwanichkanont T, Shoba J, Yip L. Hidden in Plain Sight: Umbilical Melanoma. A Multicenter Propensity Score Matching Study. Int J Cancer (2018) 142(3):641–8. doi: 10.1002/ijc.31078
12. Verver D, van Klaveren D, van Akkooi ACJ, Rutkowski P, Powell B, Robert C, et al. Risk Stratification of Sentinel Node–Positive Melanoma Patients Defines Surgical Management and Adjuvant Therapy Treatment Considerations. Eur J Cancer (2018) 96:25–33. doi: 10.1016/j.ejca.2018.02.022
13. Suzuki S, Yoshida Y, Shiomi T, Yanagihara S, Kimura R, Yamamoto O. Melanoma of the Umbilicus: A Patient Report, Precaution in Operative And Review of the Relevant Anatomy. Dermatol Surg (2003) 29(4):405–7. doi: 10.1094/dss.2003.00544.x
14. Mungas C, Romani J, Munoz C, Luelmo J. Navel Melanoma: Not Always Easy to Detect Not Always Difficult To Remove. Dermatol Online J (2008) 14(11):20.
15. Campos-Munoz L, Quesada-Cortés A, Ruiz E, Casaldo M, Pizzarro A. Primary Melanoma of the Umbilicus Appearing as Ophthalmitis. Clin Exp Dermatol (2007) 32(3):322–4. doi: 10.1111/j.1365-2230.2007.02366.x
16. Meine JG, Bailin PL. Primary Melanoma of the Umbilicus: Report of a Case and Review of the Relevant Anatomy. Dermatol Surg (2003) 29(4):405–7. doi: 10.1094/dss.2003.00544.x
17. Colonna MR, Giovannini UM, Storniolo G, Colonna U. The Umbilicus: A Rare Site for Melanoma. Clinical Considerations in Two Cases. Case Reports. J Plast Reconstr Surg Handb Surg (1999) 33(4):449–52. doi: 10.1080/02844319950159181
18. Hashiro M, Miyamoto T, Sonoda S, Okumura M. Malignant Melanoma Developing From an Intradermal Nevus. Dermatology (1998) 196(4):425–6. doi: 10.1159/000017937
19. Beniey M, Tran A, Boulva K. Mapping Sentinel Lymph Nodes in Cutaneous Melanoma: A Vast Array of Perioperative Imaging Modalities. Melanoma Res (2021) 31(2):108–18. doi: 10.1097/CMR.0000000000000704
20. Quaglino P, Ribero S, Osella-Abate S, Macrì L, Grassi M, Caliendo V, et al. Clinico-Pathologic Features of Primary Melanoma and Sentinel Lymph Node Predictive for Non-Sentinel Lymph Node Involvement and Overall Survival in Melanoma Patients: A Single Centre Observational Cohort Study. Surg Oncol (2011) 20(4):259–64. doi: 10.1016/j.suronc.2010.11.001
21. Testori AA, Ribero S, Indini A, Mandala M. Adjuvant Treatment of Melanoma: Recent Developments and Future Perspectives. Am J Clin Dermatol (2019) 20(6):817–27. doi: 10.4103/ajcd.ajcd_371_20
22. Quartuccio N, Garau LM, Arnone A, Pappalardo M, Rubello D, Arnone G, et al. Comparison of 99mTc-Labeled Colloid SPECT/CT and Planar Lymphoscintigraphy in Sentinel Lymph Node Detection in Patients With Melanoma: A Meta-Analysis. J Clin Med (2020) 9(6):1680. doi: 10.3390/jcm9061680
23. Kreitscher L, Altenvoerde G, Meller J, Zutt M, Funke M, Neumann C, et al. Dynamic Lymphoscintigraphy and Image Fusion of SPECT and Pénic CT-Scans Allow Mapping of Aberrant Pelvic Sentinel Lymph Nodes in Malignant Melanoma. Eur J Cancer (2003) 39(2):175–83. doi: 10.1016/s0959-8402(02)00534-8
24. Stoffels I, Boy C, Pöppel T, Kuhn J, Klötgen K, Dissemond J, et al. Association Between Sentinel Lymph Node Excision With or Without Preoperative SPECT/CT and Metastatic Node Detection and Disease-Free Survival in Melanoma. JAMA (2012) 308(10):1007–14. doi: 10.1001/jama.2012.11030
25. Tew K, Farlow D. Utility of Hybrid SPECT/CT in Primary Melanoma Lymphoscintigraphy: A Retrospective Case Series. J Med Imaging Radiat Oncol (2017) 61(2):204–11. doi: 10.1111/1754-9485.12554

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s Note: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.